热门资讯> 正文
Addex Therapeutics报告1H结果
2026-09-28 15:46
- Addex Therapeutics press release (ADXN): 1H basic and diluted loss per share remained stable at CHF 0.03 per share for the six-month periods ended June 30, 2026 and 2025.
- Cash and cash equivalents decreased to CHF 0.8 million at June 30, 2026, compared to CHF 2.3 million at June 30, 2025. The decrease of CHF 1.5 million between June 30, 2026, and June 30, 2025, is primarily due to operating activities partially offset by the sale of treasury shares and ADSs.
- Income, primarily related to the fair value of the services received from Neurosterix’s Group at zero cost, decreased by CHF 0.1 million in the six-month period ended June 30, 2026, compared to the same period ended June 30, 2025.
推荐文章
丘盛一筹 | 特朗普拒绝加监管！马斯克、黄仁勋集体预警：电力，才是AI的终极天花板
休市提醒：国庆假期将至，港股10月1日休市、10月2日复市；美股正常开市
华盛早报 | 重磅利好！房贷贴息新政下月落地；美联储“三把手”称10月不急于加息；欢创科技今日上市，昨日暗盘飙升近200%
美股前瞻 | 医药巨头豪掷20亿美元入股抗癌药企SMMT！特朗普释放美伊谈判利好；贝壳盘前巨震10%！房贷贴息政策重磅落地
苹果年内大涨约25%，市值迫近5万亿美元！资金风向生变，AI+折叠屏双重催化，果链哪些标的还能上车？
资金复盘 | 北水净买入港股近1500万港元，分别净买入友邦保险逾8亿、小米近4亿港元，沽出康方生物逾5亿港元
新股暗盘 | “大肉签”再现！欢创科技大涨近130%，中签一手赚超7500港元！
华盛早报 | 股债性价比反转！10年美债吸引力超标普500指数；英伟达狂撒1500亿美元回购逆势上升；Anthropic25财年营收飙升1088%
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
